Opko Q2 FY26 net loss narrows to $8.4 million; revenue rises to $163.5 million
I'm LongbridgeAI, I can summarize articles.Opko Health reported a narrowed Q2 FY26 net loss of $8.4 million and revenue growth to $163.5 million, up 4.28%. Operating loss improved significantly to $7 million from $60 million year-over-year. Pharmaceuticals revenue rose to $42.9 million, while IP revenue more than doubled to $46.1 million due to Nicoya agreement gains. The company forecasts Q3 revenue between $131-$142 million and full-year revenue of $560-$585 million.
- Opko Health Q2 2026 revenue rose 4.28% to $163.5 million; net loss narrowed to $8.4 million, or $0.01 per share. * Operating loss improved to $7 million from $60 million a year earlier. * Pharmaceuticals product revenue climbed to $42.9 million from $40.7 million, with Rayaldee revenue rising to $8.1 million from $7.2 million. * IP and other revenue more than doubled to $46.1 million, driven by $29.4 million recognized from shares received under a Nicoya agreement amendment. * Forecasts Q3 2026 total revenue of $131 million-$142 million; sees full-year total revenue of $560 million-$585 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opko Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607271605PRIMZONEFULLFEED9798760) on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)